Quick Answer
Eton Pharmaceuticals, Inc. reported Stockholders Equity of $26.15 million for the year ending 2025.
- Eton Pharmaceuticals, Inc. showed an increase of +7.1% in Stockholders Equity from 2024 to 2025.
- This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$9.55 million | Q2 2018: -$12.94 million | Q3 2018: -$16.41 million | Q1 2019: $19.24 million | Q2 2019: $16.70 million | Q3 2019: $12.35 million | Q1 2020: $10.62 million | Q2 2020: $7.03 million | Q3 2020: $1.39 million | Q1 2021: $21.56 million | Q2 2021: $20.74 million | Q3 2021: $15.66 million | Q1 2022: $13.38 million | Q2 2022: $13.24 million | Q3 2022: $11.18 million | Q1 2023: $11.24 million | Q2 2023: $16.73 million | Q3 2023: $16.89 million | Q1 2024: $15.49 million | Q2 2024: $13.46 million | Q3 2024: $15.98 million | Q1 2025: $24.45 million | Q2 2025: $23.96 million | Q3 2025: $23.13 million.
- Over the full 9 years of available data (2017 to 2025), Eton Pharmaceuticals, Inc.'s Stockholders Equity has grown by 480.5%.
- Historical annual values: Fiscal year 2025: $26.15 million | Fiscal year 2024: $24.43 million | Fiscal year 2023: $15.48 million | Fiscal year 2022: $13.08 million | Fiscal year 2021: $17.63 million | Fiscal year 2020: $17.63 million | Fiscal year 2019: $10.55 million | Fiscal year 2018: $26.30 million | Fiscal year 2017: -$6.87 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: